Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06053411 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Contribution of UGT2B17 to the Pharmacokinetics of Diclofenac

StatusRecruiting
PhaseEarly Phase 1
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated June 4, 2026 (before its estimated August 18, 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Dec 18, 2025 to Aug 18, 2026
    • Study completion date: Aug 18, 2026 to Dec 18, 2026
    v6
  2. Primary completion date: Aug 18, 2024 to Dec 18, 2025
    • Study completion date: Aug 18, 2024 to Aug 18, 2026
    v5
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jan 1, 2024 to Mar 1, 2024
    • Site details revised
    v4
  4. Start date: Nov 1, 2023 to Jan 1, 2024v3
  5. Study title shortened, about 15 wordsv2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this pilot study is to gather preliminary data on the (1) contribution of the understudied drug metabolizing enzyme, UDP-glucuronosyltransferase (UGT) 2B17, to the metabolism of a widely used medication, diclofenac, and (2) impact of the UGT2B17 inhibitor and natural product, curcumin, on diclofenac pharmacokinetics. Results will inform future studies aimed to assess the effects of UGT2B17 genetic polymorphisms and co-consumed xenobiotics on the pharmacokinetics and toxicity risk of diclofenac and other UGT2B17 drug substrates.
Trial Details
NCT Number NCT06053411
Lead Sponsor Washington State University
Conditions
(from sponsor)		 Interaction
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov